The endocannabinoid system and the control of glucose homeostasis
Keywords:
endocannabinoid system, endocannabinoid receptors, glucose metabolism endocrine secretion pancreasAbstract
The endogenous cannabinoid system participates in the regulation of energy homeostasis, regulation also of glucose homeostasis. It has been recently recognized as an important modulatory system in the function of brain, endocrine, and immune tissues. It appears to play a very important regulatory role in the secretion of hormones. The important elements of this system are endocannabinoid receptors (types CB1 and CB2). The endocannabinoid receptors are distributed both in the central and peripheral nervous system, in multiple peripheral tissues. Localisation are also on islets of Langerhans. Endocannabinoid system plays role in regulation of endocrine secretion in the human pancreas. This system also controls of the food intake centers of the central nervous system and gastrointestinal tract activity. The endocannabinoid system regulates not only the central and peripheral mechanisms of food intake, but also lipids synthesis and turnover in the liver and adipose tissue as well as glucose metabolism in muscle cells.
Downloads
References
Drzewoski J., Śliwińska A. Rymonabant – nadzieja w leczeniu otyłości i cukrzycy typu 2. Experimental and Clinical Diabetology 2007;7:53-63.
De Petrocellis L, Di Marzo V. An introduction to the endocannabinoid system: from the early to the latest concepts. Best Pract Res Clin Endocrinol Metab. 2009;23:1-15.
Di Marzo V. Endocannabinoids: synthesis and degradation. Rev Physiol Biochem Pharmacol. 2008;160:1-24.
Minkkilä A, Savinainen JR, Käsnänen H, Xhaard H, Nevalainen T, Laitinen JT, Poso A, Leppänen J, Saario SM. Screening of various hormone-sensitive lipase inhibitors as endocannabinoid-hydrolyzing enzyme inhibitors. Chem Med Chem. 2009;4:1253-1259.
Lunn CA, Reich EP, Fine JS, Lavey B, Kozlowski JA, Hipkin RW, Lundell DJ, Bober L. Biology and therapeutic potential of cannabinoid CB2 receptor inverse agonists. Br J Pharmacol. 2008;153:226-239.
Brus R., Nowak P.: Efekty metaboliczne endogennych kanabinoidów u ssaków. [w:] Cukrzyca w populacji wieku rozwojowego – co nowego? (red.) Otto-Buczkowska E., Cornetis, Wrocław, 2009, 55-60.
Mackie K, Stella N. Cannabinoid receptors and endocannabinoids: Evidence for New Players. AAPS Journal. 2006; 8(2): E298-E306.
Nowak P., Brus R. Układ endokanabinowy – przyszłość nowoczesnej farmakoterapii wybranych schorzeń endokrynologicznych u dzieci. w Endokrynologia wieku rozwojowego – co nowego? (red.) Otto-Buczkowska E., Cornetis, Wrocław 2008:286-293.
Bermudez-Silva FJ, Sanchez-Vera I, Suárez J, Serrano A, Fuentes E, Juan-Pico P, Nadal A, Rodríguez de Fonseca F. Role of cannabinoid CB2 receptors in glucose homeostasis in rats. Eur J Pharmacol. 2007;565:207-211.
Bermúdez-Silva FJ, Suárez Pérez J, Nadal A, Rodríguez de Fonseca F. The role of the pancreatic endocannabinoid system in glucose metabolism. Best Pract Res Clin Endocrinol Metab. 2009;23:87-102.
Cavuoto P, Wittert GA. The role of the endocannabinoid system in the regulation of energy expenditure. Best Pract Res Clin Endocrinol Metab. 2009;23:79-86.
Cota D, Sandoval DA, Olivieri M, Prodi E, D'Alessio DA, Woods SC, Seeley RJ, Obici S. Food intake-independent effects of CB1 antagonism on glucose and lipid metabolism. Obesity (Silver Spring). 2009;17:1641-1645.
D'Eon TM, Pierce KA, Roix JJ, Tyler A, Chen H, Teixeira SR. The role of adipocyte insulin resistance in the patholgenesis of obesity-related elevation in endocannabinoids. Diabetes, 2008, 57, 1262-1268.
Díaz-Asensio C, Setién R, Echevarría E, Casis L, Casis E, Garrido A, Casis O. Type 1 diabetes alters brain cannabinoid receptor expression and phosphorylation status in rats. Horm Metab Res. 2008;40:454-458.
Kunos G. Understanding metabolic homeostasis and imbalance: what is the role of the endocannabinoid system? Am J Med. 2007;120(9 Suppl 1):S18-24; discussion S24.
Kunos G, Osei-Hyiaman D, Liu J, Godlewski G, Bátkai S. Endocannabinoids and the control of energy homeostasis. J Biol Chem. 2008;283:33021-33025.
Matias I, Cristino L, Di Marzo V. Endocannabinoids: some like it fat (and sweet too). J Neuroendocrinol. 2008;20 Suppl 1:100-109.
Nogueiras R, Rohner-Jeanrenaud F, Woods SC, Tschöp MH. The endocannabinoid system and the control of glucose homeostasis. J Neuroendocrinol. 2008;20 Suppl 1:147-151.
Nogueiras R, Diaz-Arteaga A, Lockie SH, Velásquez DA, Tschop J, López M, Cadwell CC, Diéguez C, Tschöp MH. The endocannabinoid system: role in glucose and energy metabolism. Pharmacol Res. 2009;60:93-98
Richard D, Guesdon B, Timofeeva E. The brain endocannabinoid system in the regulation of energy balance. Best Pract Res Clin Endocrinol Metab. 2009;23:17-32.
Scheen AJ, Paquot N. Inhibitors of cannabinoid receptors and glucose metabolism. Curr Opin Clin Nutr Metab Care. 2008;11:505-511.
Sudano I, Périat D, Noll G. [The endocannabinoid system]. Praxis (Bern 1994). 2008;97: 375-380.
Wang J, Ueda N. Role of the endocannabinoid system in metabolic control. Curr Opin Nephrol Hypertens. 2008;17:1-10.
Komorowski J, Stępień H. Rola układu endokannabinoidowego w regulacji czynności dokrewnej i kontroli równowagi energetycznej człowieka. Postepy Hig Med Dosw (Online). 2007;61:99-105.
Pagano C, Pilon C, Calcagno A, Urbanet R, Rossato M, Milan G, Bianchi K, Rizzuto R, Bernante P, Federspil G, Vettor R. The endogenous cannabinoids system stimulates glucose uptake in human fat cells via phosphatidylinositol 3-kinase and calcium dependent mechanism. J. Clin. Endocrinol. Metab., 2007, 92, 4810-4819.
Pagano C, Rossato M, Vettor R. Endocannabinoids, adipose tissue and lipid metabolism. J Neuroendocrinol. 2008;20 Suppl 1:124-129.
Vettor R, Pagano C. The role of the endocannabinoid system in lipogenesis and fatty acid metabolism. Best Pract Res Clin Endocrinol Metab. 2009;23:51-63.
Lipina C, Stretton C, Hastings S, Hundal JS, Mackie K, Irving AJ, Hundal HS. Regulation of MAP kinase-directed mitogenic and protein kinase B-mediated signaling by cannabinoid receptor type 1 in skeletal muscle cells. Diabetes. 2010;59:375-85.
Pagotto U, Marsicano G, Cota D, Lutz B, Pasquali R. The emerging role of the endocannabinoid system in endocrine regulation and energy balance. Endocrinol. Rev., 2006, 27, 73-100.
Rieder SA, Chauhan A, Singh U, Nagarkatti M, Nagarkatti P. Cannabinoid-induced apoptosis in immune cells as a pathway to immunosuppression. Immunobiology. 2010;215:598-605.
Bermúdez-Siva FJ, Serrano A, Diaz-Molina FJ, Sánchez Vera I, Juan-Pico P, Nadal A, Fuentes E, Rodríguez de Fonseca F. Activation of cannabinoid CB1 receptors induces glucose intolerance in rats. Eur. J. Pharmacol., 2006, 531, 282-284.
Bermúdez-Silva FJ, Suárez J, Baixeras E, Cobo N, Bautista D, Cuesta-Muoz AL, Fuentes E, Juan-Pico P, Castro MJ, Milman G, Mechoulam R, Nadal A, Rodríguez de Fonseca F. Presence of functional cannabinoid receptors in human endocrine pancreas. Diabetologia, 2008, 51, 476-487.
Duvivier VF, Delafoy-Plasse L, Delion V, Lechevalier P, Le Bail JC, Guillot E, Pruniaux MP, Galzin AM. Beneficial effect of a chronic treatment with rimonabant on pancreatic function and beta-cell morphology in Zucker Fatty rats. Eur J Pharmacol. 2009; 616:314-320.
Nakata M, Yada T. Cannabinoids inhibit insulin secretion and cytosolic Ca2+ oscillation in islet beta-cells via CB1 receptors. Regul Pept. 2008;145:49-53.
Tharp WG, Lee YH, Maple RL, Pratley RE. The cannabinoid CB1 receptor is expressed in pancreatic delta-cells. Biochem Biophys Res Commun. 2008;372:595-600
Bermúdez-Silva FJ, Suárez Pérez J, Nadal A, Rodríguez de Fonseca F. The role of the pancreatic endocannabinoid system in glucose metabolism. Best Pract Res Clin Endocrinol Metab. 2009;23:87-102.
Eckardt K, Sell H, Taube A, Koenen M, Platzbecker B, Cramer A, Horrighs A, Lehtonen M, Tennagels N, Eckel J. Cannabinoid type 1 receptors in human skeletal muscle cells participate in the negative crosstalk between fat and muscle. Diabetologia. 2009; 52:664-674.
Motaghedi R, McGraw TE. The CB1 endocannabinoid system modulates adipocyte insulin sensitivity. Obesity (Silver Spring). 2008;16:1727-1734.
Juan-Picó P, Fuentes E, Bermúdez-Silva FJ, Javier Díaz-Molina F, Ripoll C, Rodríguez de Fonseca F, Nadal A. Cannabinoid receptors regulate Ca2+ signals and insulin secretion in pancreatic b-cell. Cell Calcium, 2006, 39, 155-162.
Linari G, Agostini S, Amadoro G, Ciotti MT, Florenzano F, Improta G, Petrella C, Severini C, Broccardo M. Involvement of cannabinoid CB1- and CB2-receptors in the modulation of exocrine pancreatic secretion. Pharmacol Res. 2009;59: 207-214.
Zhang F., Hong S., Stone V., Smith P.J.: Expression of cannabinoid CB1 receptors in models of diabetic nephropathy. J. Pharmacol. Exp. Ther., 2007, 323, 508-515.
Zhang F, Challapalli SC, Smith PJ. Cannabinoid CB(1) receptor activation stimulates neurite outgrowth and inhibits capsaicin-induced Ca(2+) influx in an in vitro model of diabetic neuropathy. Neuropharmacology. 2009;57:88-96
Toth CC, Jedrzejewski NM, Ellis CL, Frey WH. Cannabinoid-mediated modulation of neuropathic pain and microglial accumulation in a model of murine type I diabetic peripheral neuropathic pain. Mol Pain. 2010;6:16.
Fride E.: The endocannabinoid – CB1 receptor system in pre- and postnatal life. Eur. J. Pharmacol., 2004, 500, 289-297.
Davis SN, Perkins JM. Role of the endocannabinoid system in management of patients with type 2 diabetes mellitus and cardiovascular risk factors. Endocr Pract. 2007;13:790-804.
Di Marzo V.: The endocannabinoid system in obesity and type 2 diabetes. Diabetologia, 2008; 51: 1356-1367.
Fride E., Bregman T., Kirkham T.C.: Endocanabinnoids and food intake: Newborn suckling and appetite regulation in adulthood. Exp. Biol. Med., 2005, 230, 225-234.
Janero DR, Makriyannis A. Cannabinoid receptor antagonists: pharmacological opportunities, clinical experience, and translational prognosis. Expert Opin Emerg Drugs. 2009;14:43-65.
Scheen AJ, Paquot N. Use of cannabinoid CB1 receptor antagonists for the treatment of metabolic disorders. Best Pract Res Clin Endocrinol Metab. 2009;23:103-116.
Scheen AJ. The endocannabinoid system: a promising target for the management of type 2 diabetes. Curr Protein Pept Sci. 2009;10:56-74.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2011 Medical Journal of the Rzeszow University and the National Medicines Institute, Warsaw
This work is licensed under a Creative Commons Attribution 4.0 International License.
Our open access policy is in accordance with the Budapest Open Access Initiative (BOAI) definition: this means that articles have free availability on the public Internet, permitting any users to read, download, copy, distribute, print, search, or link to the full texts of these articles, crawl them for indexing, pass them as data to software, or use them for any other lawful purpose, without financial, legal, or technical barriers other than those inseparable from having access to the Internet itself.
All articles are published with free open access under the CC-BY Creative Commons attribution license (the current version is CC-BY, version 4.0). If you submit your paper for publication by the Eur J Clin Exp Med, you agree to have the CC-BY license applied to your work. Under this Open Access license, you, as the author, agree that anyone may download and read the paper for free. In addition, the article may be reused and quoted provided that the original published version is cited. This facilitates freedom in re-use and also ensures that Eur J Clin Exp Med content can be mined without barriers for the research needs.
